Evelo Biosciences, Inc.
Every calculator, already run for EVLO
Open the full toolkit →You have the numbers on EVLO. Get the argument.
A written report on which of these readings actually decide the outcome for Evelo Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Ownership & short interest
Insider Trading Activity for EVLO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridg…
EVLO — frequently asked
Is EVLO a buy right now?
Wall Street's consensus rating on Evelo Biosciences, Inc. is none. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Evelo Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Evelo Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EVLO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Evelo Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.